Merck Licenses SciBrunch Cancer Drug for $2.13B
Merck agreed to pay up to $2.13 billion for global rights to SciBrunch Therapeutics experimental oral cancer drug. The deal includes $400 million upfront to bolster its oncology pipeline.
Insights:
Merck agreed on Monday to pay up to $2.13 billion for global rights to an experimental cancer treatment from China-based SciBrunch Therapeutics. The licensing deal expands Merck's oncology pipeline ahead of anticipated patent expirations for Keytruda later this decade. The acquisition diversifies Merck's revenue streams as its top-selling immunotherapy faces generic competition.
